This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

39/100

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Tau biomarkers

Topic: Brain proteins, microglia and lab models

Background Alzheimer disease (AD) is characterized by the accumulation of beta-amyloid (Aβ) plaques and neurofibrillary tangles composed of hyperphosphorylated tau, which together lead to neurodegeneration and cognitive decline. Current therapeutic approaches have primarily aimed to reduce pathological aggregates of either Aβ or tau, yet phase 3 clinical trials of these approaches have thus far failed to delay disease progression in humans. Strong preclinical evidence indicates that these two abnormally aggregated proteins interact synergistically to drive downstream neurodegeneration.

Key findings

Current therapeutic approaches have primarily aimed to reduce pathological aggregates of either Aβ or tau, yet phase 3 clinical trials of these approaches have thus far failed to delay disease progression in humans.
Strong preclinical evidence indicates that these two abnormally aggregated proteins interact synergistically to drive downstream neurodegeneration.
Therefore, combinatorial therapies that concurrently target both Aβ and tau might be needed for effective disease modification.
Methods A combinatorial vaccination approach was designed to concurrently target both Aβ and tau pathologies.

Why it matters

In Tau22/5xFAD bigenic mice, a combination vaccine targeting both amyloid-beta and tau was tested to reduce pathology. This is preclinical animal work, and the text notes that phase 3 trials of approaches targeting either protein alone have so far failed to delay disease progression in humans.

New to this subject? Start with our plain-English guide: Blood tests & biomarkers →

Study details

Study designclinical trial
Evidence strengthLow

How this study scored 39/100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported and randomised / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Alzheimer's research & therapy)
Journal's citation record	1 / 4	Alzheimer s Research & Therapy: journal h-index 146 (OpenAlex, 2026-10-29)
Study design	0 / 12	Design recorded as “clinical trial”, which our rubric does not rank (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	2 / 5	2019 — within 10 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Laboratory or animal study (title names “5xfad”) — scores zero
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	3 / 7	Cited 37 times (OpenAlex, 2026-10-10)
Citations per year	2 / 5	4.1 citations a year over 9 year(s) since 2019
Impact for its field and year	2 / 6	Cited 2.4× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	2 / 4	Cited 18 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	2 / 4	Last-listed author Anahit Ghochikyan: h-index 30 (OpenAlex, whole career)
Institution's track record	1 / 3	University of California, Irvine: institution h-index 1,195 (OpenAlex)
Multi-centre collaboration	2 / 3	OpenAlex lists 4 institution(s) in 2 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 31847886)
Free to read	2 / 2	Free to read
Total	39 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

APA 7th

Davtyan, H., Hovakimyan, A., Kiani Shabestari, S., Antonyan, T., Coburn, M. A., Zagorski, K., et al. (2019). Testing a MultiTEP-based combination vaccine to reduce Aβ and tau pathology in Tau22/5xFAD bigenic mice. Alzheimer's research & therapy. https://doi.org/10.1186/s13195-019-0556-2

Vancouver

Davtyan H, Hovakimyan A, Kiani Shabestari S, Antonyan T, Coburn MA, Zagorski K, et al. Testing a MultiTEP-based combination vaccine to reduce Aβ and tau pathology in Tau22/5xFAD bigenic mice. Alzheimer's research & therapy. 2019. doi:10.1186/s13195-019-0556-2. PMID: 31847886.

BibTeX

@article{davtyan2019-31847886,
  author  = {Davtyan, H. and Hovakimyan, A. and Kiani Shabestari, S. and Antonyan, T. and Coburn, M. A. and Zagorski, K. and Chailyan, G. and Petrushina, I. and others},
  title   = {{Testing a MultiTEP-based combination vaccine to reduce Aβ and tau pathology in Tau22/5xFAD bigenic mice}},
  journal = {Alzheimer's research \& therapy},
  year    = {2019},
  doi     = {10.1186/s13195-019-0556-2},
  pmid    = {31847886},
  url     = {https://doi.org/10.1186/s13195-019-0556-2}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Tau biomarkers

Also tagged “phosphorylated”

732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.

Similar studies

More on Tau biomarkers

See all studies in Tau biomarkers →